Tilray | TRLY - Net Income

Stock Price
9.55
Daily Change
0.11 1.17%
Monthly
-8.26%
Yearly
894.79%
Q1 Forecast
9.24

Tilray reported $-44.93M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acasti Pharma USD -938K 2.42M Sep/2025
Akebia Therapeutics USD 6.11M 28.92M Mar/2025
Alaunos Therapeutics USD -1.16M 417K Sep/2025
Aurora Cannabis CAD -51.47M 36.26M Sep/2025
Avita Medical AUD -11.62M 1.7M Dec/2025
Canopy Growth CAD -1.64M 39.89M Sep/2025
Cronos Group USD -1.82M 24.14M Dec/2025
Dianthus Therapeutics USD -36.76M 5.13M Sep/2025
Divis Laboratories Ltd INR 5.83B 1.06B Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
IQVIA Holdings USD 514M 183M Dec/2025
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Moderna USD -200M 625M Sep/2025
Organigram Holdings CAD -37.96M 31.67M Sep/2025
Organon & Co USD 160M 15M Sep/2025
Revvity USD 98.36M 51.71M Dec/2025
Tectonic Therapeutic USD -19.04M 940K Sep/2025
Tilray USD -44.93M 44.61M Sep/2025
Viatris USD -340.1M 211.9M Dec/2025
Xeris Pharmaceuticals USD 621K 2.55M Sep/2025